Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication ZALTRAP, in combination with fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. FDA label
ziv-aflibercept · 4 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| ziv-aflibercept | BIOLOGICAL | - |
DISEASE CHARACTERISTICS: * Histologically confirmed non-Hodgkin's lymphoma OR primary or metastatic solid tumor located in at least one of the following sites: * Liver * Soft tissue * Pelvis * Other site that is suitable for delayed contrast-enhancing MRI * Relapsed or refractory disease ...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
Ziv-aflibercept is being studied in cancer and lymphoma, specifically in adults with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma. The clinical program has focused on patients whose disease has returned or stopped responding to prior treatment. It remains an investigational therapy in Phase 1 development.
Ziv-aflibercept targets PGF and VEGFA, two proteins that promote blood vessel growth. It is an inhibitor that binds these vascular endothelial growth factor pathway ligands, aiming to block the signaling that supports tumor angiogenesis. This mechanism is being explored in oncology settings.
Regeneron Pharmaceuticals, Inc. is developing ziv-aflibercept. The company trades on the Nasdaq under the ticker REGN. Regeneron is the sponsor associated with the clinical development program for this monoclonal antibody in oncology.
Ziv-aflibercept is in Phase 1 clinical development. It is an investigational agent and has not been established as approved for the cancer and lymphoma indications being studied. The Phase 1 program enrolled adults with advanced solid tumors or non-Hodgkin's lymphoma.
Ziv-aflibercept has been evaluated in Phase 1 trials including NCT00083213, NCT00082823, NCT00045266, and NCT00036946. These studies treated adults with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma in the United States. All listed trials are completed, and no trials are currently active.
Across the reported Phase 1 studies, total enrollment was approximately 50 patients. The trials were uncontrolled, non-randomized, and not double blinded, and they enrolled adults aged 18 years and older with advanced solid tumors or non-Hodgkin's lymphoma. Enrollment figures for some individual studies were not reported.